AstraZeneca PLC - Result of AGM
Results of Annual General Meeting held on
AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 9 - 12 were passed as special resolutions; all other resolutions were passed as ordinary resolutions.
|
|
Resolution |
Votes for |
% of votes cast |
Votes against |
% of votes cast |
Votes cast in total |
Total votes cast as a % of issued share capital |
Votes withheld |
|
1 |
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended |
1,192,725,049 |
99.89 |
1,302,321 |
0.11 |
1,194,027,370 |
77.00 |
3,895,442 |
|
2 |
To confirm the 2024 interim dividends |
1,195,017,493 |
99.91 |
1,103,545 |
0.09 |
1,196,121,038 |
77.14 |
1,801,779 |
|
3 |
To re-appoint PricewaterhouseCoopers LLP as Auditor |
1,188,274,693 |
99.35 |
7,772,140 |
0.65 |
1,196,046,833 |
77.13 |
1,875,089 |
|
4 |
To authorise the Directors to agree the remuneration of the Auditor |
1,194,967,897 |
99.91 |
1,035,521 |
0.09 |
1,196,003,418 |
77.13 |
1,919,068 |
|
5a |
To re-elect Michel Demaré as a Director |
1,192,597,854 |
99.72 |
3,348,956 |
0.28 |
1,195,946,810 |
77.13 |
1,975,799 |
|
5b |
To re-elect |
1,194,161,249 |
99.85 |
1,828,809 |
0.15 |
1,195,990,058 |
77.13 |
1,932,568 |
|
5c |
To re-elect |
1,193,240,137 |
99.77 |
2,730,661 |
0.23 |
1,195,970,798 |
77.13 |
1,951,782 |
|
5d |
To re-elect |
1,192,344,687 |
99.70 |
3,578,792 |
0.30 |
1,195,923,479 |
77.12 |
1,999,129 |
|
5e |
To re-elect |
1,193,753,030 |
99.82 |
2,163,488 |
0.18 |
1,195,916,518 |
77.12 |
2,006,023 |
|
5f |
To elect |
1,195,603,172 |
99.97 |
315,680 |
0.03 |
1,195,918,852 |
77.12 |
2,003,690 |
|
5g |
To elect |
1,173,872,808 |
98.16 |
22,033,446 |
1.84 |
1,195,906,254 |
77.12 |
2,016,215 |
|
5h |
To elect |
1,195,604,027 |
99.97 |
301,466 |
0.03 |
1,195,905,493 |
77.12 |
2,017,116 |
|
5i |
To re-elect |
1,195,604,497 |
99.97 |
300,003 |
0.03 |
1,195,904,500 |
77.12 |
2,018,109 |
|
5j |
To re-elect |
1,194,823,605 |
99.91 |
1,048,387 |
0.09 |
1,195,871,992 |
77.12 |
2,050,618 |
|
5k |
To re-elect |
1,149,796,685 |
96.15 |
46,101,055 |
3.85 |
1,195,897,740 |
77.12 |
2,024,865 |
|
5l |
To re-elect |
1,195,574,262 |
99.97 |
310,802 |
0.03 |
1,195,885,064 |
77.12 |
2,037,477 |
|
5m |
To re-elect |
1,193,299,249 |
99.79 |
2,566,024 |
0.21 |
1,195,865,273 |
77.12 |
2,057,343 |
|
5n |
To re-elect |
980,843,680 |
83.11 |
199,351,215 |
16.89 |
1,180,194,895 |
76.11 |
17,727,254 |
|
6 |
To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended |
1,152,784,239 |
96.40 |
43,097,131 |
3.60 |
1,195,881,370 |
77.12 |
2,041,421 |
|
7 |
To authorise limited political donations |
1,152,744,556 |
96.90 |
36,841,029 |
3.10 |
1,189,585,585 |
76.72 |
8,336,892 |
|
8 |
To authorise the Directors to allot shares |
1,108,802,235 |
92.72 |
87,039,743 |
7.28 |
1,195,841,978 |
77.12 |
2,080,506 |
|
9 |
To authorise the Directors to disapply pre-emption rights |
1,057,501,935 |
88.45 |
138,089,003 |
11.55 |
1,195,590,938 |
77.10 |
2,331,672 |
|
10 |
To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments |
1,011,405,311 |
84.89 |
179,961,211 |
15.11 |
1,191,366,522 |
76.83 |
6,556,062 |
|
11 |
To authorise the Company to purchase its own shares |
1,186,436,265 |
99.24 |
9,028,112 |
0.76 |
1,195,464,377 |
77.10 |
2,458,408 |
|
12 |
To reduce the notice period for general meetings |
1,109,717,539 |
92.81 |
85,989,258 |
7.19 |
1,195,706,797 |
77.11 |
2,216,021 |
A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Issued capital
As at
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE